

Special Issue

Rethinking Tuberculosis Treatment: Integrating Antimicrobial Compounds, Host Responses, and Comorbidities

Message from the Guest Editors

Tuberculosis (TB) continues to pose a major global health challenge, underscored by the limited efficacy of current therapeutic regimens, the rapid emergence of drug-resistant *Mycobacterium tuberculosis* strains, and heterogeneous treatment outcomes across patient populations. The failure to effectively integrate antimicrobial drug discovery with host immune modulation, vaccine development, and disease-associated comorbidities has contributed to persistent gaps in TB control. This Special Issue focuses on recent advances in anti-tubercular antimicrobial compounds, resistance mechanisms, and therapeutic strategies that extend beyond conventional pathogen-centered approaches. Emphasis is placed on the development of novel drugs, optimization of existing antibiotics, and host-directed therapies that enhance treatment efficacy and shorten disease duration. In parallel, contributions addressing vaccine strategies and the influence of TB-associated comorbidities are welcomed. By integrating mechanistic insights with translational perspectives, this Issue aims to highlight innovative and realistic therapeutic pathways for improved TB management in the era of antimicrobial resistance.

Guest Editors

Dr. Ashok Aspatwar

Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33520 Tampere, Finland

Dr. Wenping Gong

Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China

Deadline for manuscript submissions

30 November 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/264433

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)